BI 655064
Sponsors
Boehringer Ingelheim
Conditions
Arthritis, RheumatoidHealthyLupus NephritisPurpura, Thrombocytopenic, Idiopathic
Phase 1
Single Rising Dose Study (Intravenous Infusion and Subcutaneous Injection) of BI 655064 in Healthy Male Volunteers
CompletedNCT01510782
Start: 2012-01-31End: 2012-09-30Updated: 2013-11-01
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy
CompletedNCT01751776
Start: 2012-12-18End: 2015-04-27Updated: 2024-03-21
Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers
CompletedNCT01917916
Start: 2013-08-05End: 2014-05-14Updated: 2023-08-09
Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).
TerminatedNCT02009761
Start: 2013-12-18End: 2016-04-26Updated: 2024-03-15
Safety and Pharmacokinetics of Multiple Doses of BI 655064 in Healthy Chinese Male Volunteers
CompletedNCT02331277
Start: 2015-09-01End: 2016-05-25Updated: 2023-08-21